Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers

May 21, 2018 – Loxo Oncology completed a rolling new drug application (NDA) to the FDA in March 2018 for larotrectinib (LOXO-101), a pan-TRK inhibitor codeveloped by Bayer. If approved, larotrectinib would be available as a treatment for both adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion. The ongoing simultaneous evaluation of larotrectinib in adult and pediatric patients is a rarity in the oncology space, said … (leggi tutto)